Observers characterized the dismissals, policy reversals, and controversies at the FDA as a soap opera, total disarray, and potentially, unprincipled ...
Weight loss drugs are set to become a disproportionate share of Lilly's business.
33mon MSN
Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback